Related Experiment Video
Updated: May 11, 2026
08:25
Radiation Planning Assistant - A Streamlined, Fully Automated Radiotherapy Treatment Planning System
Published on: April 11, 2018
The American Brachytherapy Society consensus statement for accelerated partial breast irradiation
Chirag Shah1, Frank Vicini, David E Wazer
1Department of Radiation Oncology, Washington University School of Medicine, Saint Louis, MO, USA.
Brachytherapy
|April 27, 2013
Summary
Accelerated partial breast irradiation (APBI) guidelines help select early-stage breast cancer patients for optimal outcomes. These guidelines ensure quality practice for breast-conserving therapy, improving patient satisfaction.
Area of Science:
- Oncology
- Radiation Oncology
- Surgical Oncology
Background:
- Breast-conserving therapy is a standard treatment for early-stage breast cancer.
- Accelerated partial breast irradiation (APBI) offers a shorter treatment course compared to whole breast irradiation.
- Evidence supporting APBI efficacy and safety has grown significantly.
Purpose of the Study:
- To establish clinical guidelines for the quality practice of APBI.
- To define patient selection criteria for APBI in early-stage breast cancer.
- To optimize clinical outcomes and patient satisfaction with APBI.
Main Methods:
- Literature review of randomized trials and clinical series.
- Expert consensus from the American Brachytherapy Society.
- Development of evidence-based patient evaluation and selection criteria.
Main Results:
- APBI demonstrates excellent clinical outcomes with over 10-year follow-up.
- Key patient selection factors include age (≥50), tumor size (≤3cm), negative margins, and no lymphovascular invasion or nodal involvement.
- Consistent dosimetric guidelines are crucial for target coverage and toxicity reduction.
Conclusions:
- The guidelines provide clinicians with criteria for appropriate APBI patient selection.
- Implementing these guidelines aims to optimize APBI clinical outcomes and patient satisfaction.
- Ongoing evaluation and revision will incorporate future research for refined patient selection.
